Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Uniflox is a brand name for flucloxacillin, a narrow-spectrum beta-lactam antibiotic of the penicillin class, specifically categorized as a penicillinase-resistant penicillin. Manufactured by Navesta Pharmaceuticals, it is indicated for the treatment of bacterial infections caused by Gram-positive organisms, particularly penicillinase-producing staphylococci. Flucloxacillin exerts its antibacterial effect by binding to penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. This binding inhibits the transpeptidation enzymes responsible for cross-linking peptidoglycan chains, thereby disrupting cell wall synthesis and leading to bacterial cell lysis. Uniflox is typically administered orally and is available in a 500 mg capsule dosage form.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on flucloxacillin (Navesta Pharmaceuticals).